362.50p+0.00 (+0.00%)26 May 2022, 17:03
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Jump to:

Maxcyte INC Fundamentals

Company NameMaxcyte INCLast Updated2022-05-26
IndustryDiagnostics & ResearchSectorHealthcare
Shares in Issue101.540 mMarket Cap£368.08 m
PE Ratio0.00Dividend per Share0
Dividend Yield0Dividend Cover0
EPS-$0.21EPS Growth (%)0
PEG0DPS Growth (%)0
Debt Ratio0.0455Debt Equity Ratio0.0487
Asset Equity Ratio1.1097Cash Equity Ratio0.9393
Quick Ratio16.5305Current Ratio17.09
Price To Book Value1.7665ROCE0

Maxcyte INC Dividends

TypeEx-DatePay DateCurrencyNet DividendYear Total

Maxcyte INC Company Financials

Assets202120202019
Tangible Assets$13.37 m$6.49 m$5.53 m
Intangible Assets000
Investments000
Total Fixed Assets$13.69 m$6.53 m$5.53 m
Stocks$5.20 m$4.32 m$3.70 m
Debtors000
Cash & Equivalents$255.04 m$34.76 m$16.71 m
Other Assets000
Total Assets$284.12 m$51.78 m$29.99 m
Liabilities202120202019
Creditors within 1 year$15.62 m$11.61 m$9.34 m
Creditors after 1 year$5.61 m$6.94 m$7.04 m
Other Liabilities000
Total Liabilities$21.22 m$18.55 m$16.38 m
Net assets$262.90 m$33.23 m$13.60 m
Equity202120202019
Called up share capital$1.01 m$773,800.00$574,000.00
Share Premium$376.19 m$127.67 m$96.43 m
Profit / Loss-$19.08 m-$11.82 m-$12.89 m
Other Equity$262.90 m$33.23 m$13.60 m
Preference & Minorities000
Total Capital Employed$262.90 m$33.23 m$13.60 m
Ratios202120202019
Debt Ratio$0.02$0.16$0.33
Debt-to-Equity$0.02$0.19$0.49
Assets / Equity1.10971.10971.1097
Cash / Equity0.93930.93930.9393
EPS-$0.21-$0.17-$0.23
Cash Flow202120202019
Cash from operating activities-$10.68 m-$8.78 m-$8.80 m
Cashflow before financing$224.04 m$20.12 m$3.51 m
Increase in Cash$29.03 m$3.54 m$3.96 m
Income202120202019
Turnover$33.89 m$26.17 m$21.62 m
Cost of sales$3.65 m$2.77 m$2.50 m
Gross Profit$30.25 m$23.40 m$19.12 m
Operating Profit-$18.19 m-$11.06 m-$12.42 m
Pre-Tax profit-$19.08 m-$11.82 m-$12.89 m

Maxcyte INC Company Background

SectorHealthcare
ActivitiesMaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.
Latest Interim Date13 Sep 2021
Latest Fiscal Year End Date22 Mar 2022

Maxcyte INC Directors

AppointedNamePosition
2022-03-25Ms. Amanda L. MurphyChief Financial Officer
2022-03-25Mr. Thomas M. RossEVP, Global Sales & Marketing
2022-03-25Mr. Maher MasoudEVP and General Counsel
2022-03-07Mr. Cenk SumenChief Scientific Officer

Maxcyte INC Contact Details

Company NameMaxCyte Inc
Address22 Firstfield Road, Suite 110, Gaithersburg, 20878
Telephone+1 301 944-1700
Websitehttps://www.maxcyte.com

Maxcyte INC Advisors

RegistrarCapita Asset Services
Phone+44 1534847000
Fax+44 1534847001
AuditorAronson LLC
Phone+1 301 231-6200
Fax+1 301 231-7630
SolicitorCooley LLP
Phone+1 703 456-8000
Financial PR AdviserConsilium Strategic Communications
Phone+44 2037095700
SolicitorFeldhaus Law Group, P.C.
SolicitorTravers Smith LLP
Phone+44 2072953000
Fax+44 2072953500
SolicitorNorton Rose Fulbright US LLP
Nominated AdviserPanmure Gordon (UK) Ltd
Phone+44 2078862500
StockbrokerPanmure Gordon (UK) Ltd
Phone+44 2078862500